Soligenix (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The FDA has cleared Soligenix Inc's (NASDAQ: SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous
Soligenix, Inc. announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for a Phase 2a clinical trial entitled, Pilot Study of SGX945 in the.
The FDA has cleared Soligenix Inc's SNGX Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous ulcers…